NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosisCecilie Ammitzbøll, Finn Sellebjerg, Rikke Ratzer et al.|Multiple Sclerosis and Related Disorders|2023Cited by 13
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysisLisa G Schoof, Jeppe Romme Christensen, Brit Ellen Rød et al.|Multiple Sclerosis and Related Disorders|2025Cited by 3